Trial Profile
A study investigating the efficacy of ceritinib in crizotinib pre-treated, ALK-positive patients with advanced non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2016
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Jan 2016 New trial record